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Protocol
AbstrACt
Introduction Relatively little is known about the long-term 
health of former elite rugby players, or former sportspeople 
more generally. As well as the potential benefits of being 
former elite sportspersons, there may be potential health 
risks from exposures occurring during an individual’s playing 
career, as well as following retirement. Each contact sport 
has vastly different playing dynamics, therefore exposing 
its players to different types of potential traumas. Current 
evidence suggests that these are not necessarily comparable 
in terms of pathophysiology, and their potential long-term 
adverse effects might also differ. There is currently limited but 
increasing evidence that poorer age-related and neurological 
health exists among former professional sportsmen exposed 
to repetitive concussions; however the evidence is limited on 
rugby union players, specifically.
Methods and analysis We present the protocol for a 
cross-sectional study to assess the association between 
self-reported history of concussion during a playing career, 
and subsequent measures of healthy ageing and neurological 
and cognitive impairment. We are recruiting a sample of 
approximately 200 retired rugby players (former Oxford and 
Cambridge University rugby players and members of the 
England Rugby International Club) aged 50 years or more, 
and collecting a number of general and neurological health-
related outcome measures though validated assessments. 
Biomarkers of neurodegeneration (neurofilaments and tau) 
will be also be measured. Although the study is focusing on 
rugby union players specifically, the general study design and 
the methods for assessing neurological health are likely to be 
relevant to other studies of former elite sportspersons.
Ethics and dissemination The study has been approved 
by the Ethical Committee of London School of Hygiene and 
Tropical Medicine (reference: 11634-2). It is intended that 
results of this study will be published in peer-reviewed 
medical journals, communicated to participants, the general 
public and all relevant stakeholders.
IntroduCtIon 
The evidence relating to head trauma in sport 
and the subsequent risks of neurological 
disease have been previously been reviewed, 
and it has been established that sports 
involving repeated head trauma may have an 
increased risk of neurodegenerative disease 
in the long term.1 Furthermore, there are 
now plausible mechanisms for these effects, 
and a recognition that these problems do not 
just occur in former boxers, but in a variety of 
sports involving repeated concussions,2 and 
possibly also in sports in which low-level head 
trauma is common.3 These neurodegener-
ative effects include potentially increased 
risks of impaired cognitive function and 
dementia,4–7 Parkinson’s disease (PD)8–13 and 
amyotrophic lateral sclerosis (ALS).3 14–19 The 
term chronic traumatic encephalopathy (CTE) 
was introduced as a clinicopathological 
construct for the neurodegeneration associ-
ated with American football and wrestling20 
(see table 1).
Each contact sport has vastly different 
playing dynamics thereby exposing its players 
to different types of potential traumas. 
Current evidence suggests that these are not 
necessarily comparable in terms of pathophys-
iology, and hence in terms of their potential 
long-term adverse effects on health. There 
is currently limited but increasing evidence 
that poorer general and neurological health 
exists among professional sportsmen exposed 
strengths and limitations of this study
 ► The study will provide meaningful data on the 
burden of health and neurological health among 
retired rugby players (in only 2 years).
 ► The cross-sectional design does not prevent the 
potential for recall bias and selection bias.
 ► Results may  not be immediately generalisable to 
current players as in the last 30 years playing rules 
and conditions have changed.
2 Gallo V, et al. BMJ Open 2017;7:e017990. doi:10.1136/bmjopen-2017-017990
Open Access 
to repetitive concussions; however, there is little evidence 
from rugby union players.21–23
Decq et al21 investigated retired French-speaking high-
level sportsmen, aged 45–65 years, who had played 
sports for at least 10 years. Mild cognitive disorder was 
lower in players of other sports (40.4%) than in former 
rugby players (56.6%) (P=0.005). However, after adjust-
ment for smoking and higher education, no association 
was observed between cognitive function and number 
of reported concussions.21 In New Zealand, 366 former 
players were tested on their engagement in sport, general 
health, sports injuries and concussion history, demo-
graphic information and cognitive functioning. The 
elite rugby group performed worse on tests of complex 
attention, processing speed, executive functioning and 
cognitive flexibility than the non-contact sport group, 
and worse than the community rugby group on complex 
attention. Former players who recalled one or more 
concussions had worse scores on cognitive flexibility, 
executive functioning and complex attention than players 
who did not recall experiencing a concussion.22 A recent 
Scottish study assessed 52 former Scottish international 
rugby players and 29 controls. Players performed worse 
on a test of verbal learning, and of fine coordination of 
the dominant hand; however, no statistically significant 
differences were observed on other cognitive tests. Addi-
tionally, no significant association was found between the 
number of concussions and cognitive test performance.23
Ultimately, establishing the extent of these potential 
issues will require long-term prospective studies involving 
the repeated measurement of head trauma exposures and 
repeated tests of neurological health in large numbers of 
current and former players. However, a first step in this 
process is to conduct cross-sectional studies in former 
players to assess whether there is an association between 
their history of concussion during their rugby careers, and 
subsequent measures of healthy ageing and subtle neuro-
logical and cognitive impairment. In particular, such 
cross-sectional studies can be conducted in a relatively 
short time and with ‘standard’ measures of cognitive func-
tion since impaired cognitive function is an important 
health outcome in itself, and may be a precursor of more 
serious long-term neurological effects.24
definitions of trauma and concussion
Traumatic brain injury (TBI) is usually classified as mild, 
moderate or severe, on the basis of the initial Glasgow 
Coma Scale25 recorded in emergency departments 
including the duration of any loss of consciousness; and 
duration of post-traumatic amnesia (ie, loss of memory of 
events after the injury).26 Chronic TBI represents a spec-
trum of disorders associated with long-term consequences 
after single or repetitive TBI.27 Conversely, there remains 
limited consensus on the definition of concussion. The 
2012 Zurich Consensus Statement on Concussion in Sport 
proposed that concussion and mild TBI should be viewed 
as distinct entities.28 The group defined concussion as a 
‘complex pathophysiological process affecting the brain’, 
and despite allowing for the presence of neuropatho-
logical damage, they postulated that concussive symp-
toms largely reflected a functional disturbance, typically 
resolving spontaneously with no imaging abnormality. In 
contrast, recent guidelines from the American Academy 
of Neurology for sports concussion in 2013, do not sepa-
rate concussion from mild TBI, defining concussion as ‘a 
clinical syndrome of biomechanically induced alteration 
of brain function, typically affecting memory and orienta-
tion, which may involve loss of consciousness’.29 A recent 
report30 examines why having two different pathological 
entities might be unhelpful and suggests that the Mayo 
Table 1 Glossary of definitions, adapted from Jordan32
Chronic traumatic brain injury (TBI) A spectrum of disorders associated with long-term consequences of single or 
repetitive TBI.
Chronic traumatic encephalopathy (CTE)* Prototypic chronic TBI, long-term neurological consequences of repetitive mild TBI.
Dementia pugilistica A subtype of CTE that is typically reserved for cases of severe end-stage dementia 
secondary to a long boxing career.
Chronic postconcussion syndrome* A condition in those athletes in whom post-concussion symptoms do not appear to 
resolve.
Chronic neurocognitive impairment* A rather diverse classification of chronic neurocognitive signs and symptoms 
secondary to head impact exposures and recurrent concussions that is theoretically 
distinctive from CTE.
Post-traumatic dementia† Cases in which the athlete meets clinical criteria for dementia secondary to a single 
moderate-to-severe TBI.
Post-traumatic cognitive impairment† Individuals who sustain long-term neurocognitive deficits from a single moderate-
to-severe brain injury and do not meet clinical criteria for dementia, but instead mild 
cognitive impairment.
Post-traumatic parkinsonism A Parkinsonian-like syndrome secondary to a single moderate-to-severe or 
repetitive TBI, occurring solely or as a component of CTE.
*The most clinically pertinent examples of sports-related chronic TBI.
†Consequence of a single brain injury.
 3Gallo V, et al. BMJ Open 2017;7:e017990. doi:10.1136/bmjopen-2017-017990
Open Access
Clinic TBI Classification system should cover both defi-
nitions.31 A glossary of definitions used in this protocol is 
found in table 1, adapted from Jordan.32
For the purpose of this study, we adapted the National 
Health Institute (NIH) definition of concussion.33 Partic-
ipants will be asked to report their previous concussions 
according with the following definition:
Concussion is defined as an alteration in brain func-
tion, caused by an external force. Symptoms include:
 ► A decreased level/loss of consciousness
 ► Memory loss (before or after the injury)
 ► Weakness
 ► Temporary paralysis
 ► Loss of balance
 ► Change in vision (eg, blurriness, double vision)
 ► Coordination difficulties
 ► Numbness
 ► Decreased sense of smell
 ► Difficulty understanding what others are saying
 ► Difficulty communicating with others
 ► Confusion, disorientation or slowed thinking
Please note, loss of consciousness is not required for a 
concussion to be diagnosed.
biomarkers
Research in the field of TBI biomarkers has increased 
exponentially over the last 20 years,27 34–36 with studies 
assessing biomarkers that could provide diagnostic 
and prognostic, as well as monitoring information.37 38 
However, to date, no biomarker for the long-term effects 
of concussion has been identified, although recent studies 
on cerebrospinal fluid (CSF) from sportsmen with post-
concussive symptoms suggest that a subset of these have 
biomarker signs of ongoing axonal injury and microglial 
activation.39–41
Of the biomarkers measurable in serum or other body 
fluids, those more likely to be detectable for longer time 
periods after the concussion episode, are those related to 
the axonal injury and more in generally neuroinflamma-
tion, that is neurofilament (NF) and tau protein.38 NFs 
coassemble from protein subunits to form NFs defined 
as light (light (NF-L), medium (NF-M) or heavy (NF-H) 
according to their relative molecular weights). NFs are 
one of the key structural elements of neurons, providing 
mechanical stability and determining axonal diameter. 
NFs are of particular interest because as they are structural 
elements, they may be more susceptible to mechanical 
deformation under the condition of trauma. Abnormal 
NF aggregation may contribute to the delayed or progres-
sive neuronal death and dysfunction taking place in 
neurodegenerative diseases associated with NF aggre-
gation, such as PD, ALS and Lewy body dementia.42–44 
Acute perturbations of NFs have been demonstrated in 
experimental models of TBI that produce cortical contu-
sion in combination with selective hippocampal neuronal 
death.45 A study compared serum NF-L, a biological 
marker of head trauma, in American football athletes and 
non-contact sport athletes and examined changes over 
the course of a season. Results suggest that a season of 
collegiate American football is associated with elevations 
in serum NF-L, which is indicative of axonal injury, resul-
tant of head impacts.46 NF-L has also been associated with 
head trauma severity detected by CT scan, immediately 
after the episode47 and with concussive and subconcussive 
head impacts in boxing.41 Importantly, while plasma tau 
concentration increases and disappears rapidly (within 
hours to a few days) following concussion,48 NF-L has 
prolonged increased levels lasting for many weeks.41 49 50
Phosphorylation of tau is a normal event in healthy 
neurons, but hyperphosphorylation and aggregation into 
neurofibrillary tangles is a characteristic of Alzheimer’s 
disease and CTE.51 Tau concentrations correlate with 
lesion size and outcome in severe TBI when measured in 
the ventricular CSF, while remaining unchanged in TBI 
and other forms of acute brain injury.38 Studies on mild 
TBI show increased CSF concentrations of both t–tau and 
NF–L, although the increase in CSF NF-L is greater than 
the increase in t-tau, suggesting that head impacts have 
a greater effect on long, large-calibre axons that extend 
subcortically than on short, non-myelinated axons in the 
cortex.38 After concussion, serum tau concentrations were 
found to be increased, but this increase did not correlate 
with severity of trauma and lesion load as measured using 
CT scan signs.38
Genetics
Few hypotheses on the potential role of genetics in modu-
lating the possible association between concussion and 
cognitive decline have been formulated. Specific genes 
might be associated with an increased risk of concussion 
via worse attention or executive function, or more vulner-
able brain anatomy,52 or via personality trait.53 Conversely, 
a number of genes are involved in modulating the risk 
of developing dementia and other neurodegenerative 
diseases, irrespective of concussion. Dementia risk is 
higher among carriers of the epsilon4 allele at the apoli-
poprotein E gene.54 A number of genome-wide association 
studies (GWAS) have been performed to date, enabling 
the identification of 24 loci as risk factors for PD.
rationale of the brain health and healthy AgeIng (brAIn) 
study
Recently, World Rugby (formally known as the Interna-
tional Rugby Board), has developed a process to support 
team clinicians in the recognition, assessment and 
subsequent management of elite adult players who have 
sustained a potential concussion. This process includes 
the development of a multimodal assessment: the Head 
Injury Assessment, formerly the Pitch Side Concussion 
Assessment tool.55
However, there is little clear evidence, about the 
possible long-term effects of concussion in rugby union 
players, and it is not clear if findings from other sports 
are directly generalisable to rugby players. Many sports 
involve exposure to concussion or repetitive low-level 
head trauma, and it can be argued that each sport should 
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be considered independently, due to the unique technical 
and physiological profile that a player develops over the 
course of a career.56 57 Thus, to determine the potential 
risk of long-term adverse health effects of playing rugby 
specific studies of rugby players are needed.
The BRAIN Study builds on a recent cross-sectional 
questionnaire-based study conducted by the University of 
Oxford as part of the Arthritis Research UK Centre for 
Sport, Exercise and Osteoarthritis, who have assessed the 
general and musculoskeletal health of former elite rugby 
players.58 Rugby players from the Oxford and Cambridge 
University Football Clubs (Oxbridge Blues), and 
members of the England Rugby Internationals Club—a 
membership organisation of all current and former 
England players—were recruited. Self-reported demo-
graphic factors, playing history (including head trauma), 
past medical history (including dementia, depression 
and memory impairment), and perceived health were 
collected, in addition to detailed information on muscu-
loskeletal health and pain.
A total of 319 participants have participated in this 
study to date, and 205 of those aged 50 years or older have 
agreed to be contacted again for further studies. The 205 
participants aged 50+ years who agreed to be contacted 
again will be invited to take part in the BRAIN Study.
Aim and objectives
The overall aim of the BRAIN Study is to investigate the 
possible associations between concussion in rugby and 
ageing, including physical and cognitive capabilities, 
as well intermediate neurological and musculoskeletal 
end points among former rugby players.
In order to achieve these aims the following objectives 
will be pursued:
1. To investigate the associations between self-reported 
concussion history and ageing, measured as physical 
and cognitive capabilities. This will be achieved by us-
ing the following outcome measures:
a. Physical capability outcomes: grip strength, chair 
raise and walking speed.
b. Cognitive capability outcomes: memory, reason-
ing, speed of thinking and attention, and verbal 
and numerical skills.
2. To investigate the association between self-reported 
concussion history and intermediate neurological 
end points
a. Neurological examination: a brief neurological 
examination will be video-recorded according to 
existing protocols and independently examined 
by two neurologists.
b. Intermediate neurological end points: infor-
mation using tapping test (BRAIN), smell test, 
REM-Behaviour Disorder (RBD; REM, rapid eye 
movement) Questionnaire will be collected in 
order to explore non-motor symptoms of PD and 
related disorders.
3. To investigate whether a history of concussion is as-
sociated with current tau protein and NF-L levels in 
blood (potential biomarkers of neurodegeneration), 
and how these biomarkers are in turn associated with 
the outcome measures (potential biomarkers of early 
detection of disease).
4. To assess if any other characteristic of rugby playing 
history, in addition to self-reported concussion (ie, 
length of playing at elite level, position of play, num-
ber of games played, age when started playing), or age 
at concussion is associated with any outcome measure 
(physical and cognitive capability and/or intermedi-
ate neurological outcomes).
5. To investigate the long-term musculoskeletal health 
outcomes of rugby players with particular emphasis 
on hip, knee and hand osteoarthritis allowing chang-
es over time (from the previous study to the current 
study).
In addition, we will develop a multimedia database 
(data from tests and questionnaire plus video-recorded 
neurological examination plus biobank of blood samples) 
that will serve as baseline for further tests and further 
follow-up.
study design
Participants will be invited to study clinics in London, 
Manchester or Bath. A home visit can also be arranged 
by request. Participants will be invited to bring with them 
any medication they are taking regularly for an accurate 
recording of current medication usage.
All participants will be administered a Core Module 
interview including questions on lifestyle factors, poten-
tial confounders, and extensive information on the five 
domains of physical and cognitive ability, neurological 
examination, intermediate neurological outcomes and 
musculoskeletal health.
The lifestyle questionnaire will complement that 
already administered to participants of the Oxford-based 
cross-sectional study, and will include questions on poten-
tial confounders of the association between concussion 
and physical and cognitive capability, and intermediate 
neurological outcomes. Participants will also be asked 
to donate a blood sample (a normal blood sample will 
be collected by participants seen in one of the clinics, a 
dry spot sample plus saliva swab for DNA will be collected 
from participants seen at home). At the end of the Core 
Module, all participants will also be asked to undergo some 
additional tests (the Additional Optional Module) provided 
they have sufficient time (figure 1). At the end of the 
interview, all participants will be asked some final ques-
tions on their concussion history. This will ensure that the 
interviewer is blind to the participant’s concussion history 
during the entire duration of the interview, and will also 
act as validation to confirm data previously collected. 
Participants who disclose information about their concus-
sion history during the interview, will be noted in order to 
undertake a sensitivity analysis excluding them.
The Core Module includes: (1) a lifestyle question-
naire; (2) a set of tests covering essential information on 
physical capability (height, weight, grip strength, chair 
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rise, walking speed and photo of the hands) and cogni-
tive capability (Mini-Mental State Examination (MMSE), 
Logical Memory, Digit-Symbol Substitution test, Matrix 
Reasoning, Task-set Shifting/Response Inhibition, 
Visuomotor Integration, 12-item Face-Name Associa-
tive Memory Exam (FNAME-12) and the National Adult 
Reading Test (NART)); (3) a remote neurological clinical 
examination (video-recorded); and (4) a test for subtle 
movement disorders, the BRAIN tapping test. This Core 
Module should take no longer of 1 hour and 45 min to be 
completed.
The Additional Optional Module includes: (1) a 
questionnaire investigating hand pain; (2) extra tests 
investigating the cognitive domain (Visual short-term 
memory binding, Irrelevant Distractor Paradigm); 2) 
the Unified Parkinson's Disease Rating Scale (UPDRS) 
Part II Scale to complete the neurological examination 
(not video-recorded); (3) additional tests for interme-
diate neurological outcomes (the smell test and the RBD 
Questionnaire). This Additional Optional Module should 
take no longer than an hour and half to be completed 
(figure 1). The full test/interview including core and 
additional modules should not take more than 3 hours 
and 15 min to complete.
General questionnaires
Questionnaires will be used to collect relevant informa-
tion on:
 ► Lifestyle and confounders  - All participants will be 
asked a number of questions on their lifestyle in order 
to collect information on possible confounders for 
the main analysis (smoking, alcohol, coffee, drugs, 
past medical history, sleep quality).
 ► Concussion history - At the end of the interview, 
participants will again be asked some detailed infor-
mation regarding their history of head trauma and 
concussion while playing.
 ► Musculoskeletal hand pain - A questionnaire on hand 
pain to identify possible hand osteoarthritis will be 
used involving a hand manikin (Additional Optional 
Module).
Physical ability assessment
The methodology used in the 1946 birth cohort59 will be 
leveraged to assess physical and cognitive capabilities in 
this study. This will enhance comparability of results and 
facilitate future collaborations. The most commonly used 
objective measures of physical capability for assessing 
healthy ageing, are tests of grip strength,60 61 walking 
Figure 1 Framework for data collection in the BRAIN Study by domain. *not to be collected if the participant is seen at 
home; ^subject to suitable chair availability for the participants seen at home; ~including knee bending test; #subject to 
space availability if the participant is seen at home; ҂to be administered as last item in all cases (after all ‘Core’ and Additional 
Optional Module tests). BRAIN, BRain health and healthy AgeINg; FNAME-12, 12-item Face-Name Associative Memory Exam; 
HOOS, Hip Disability and Osteoarthritis Outcome Score; KOOS, Knee Injury and Osteoarthritis Outcome Score; MMSE, Mini-
Mental State Examination; NART, National Adult Reading Test; QuIKS, Questionnaire to Identify Knee Symptoms; RBD, REM-
Behaviour Disorder; WAIS-R, Wechsler Adult Intelligence Scale-Revised; WASI, Wechsler Abbreviated Scale of Intelligence; 
WMS-R, Wechsler Memory Scale-Revised.  
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speed,60 62 63 chair rises64 and standing balance;60 these 
aim to assess physical functioning, including the capacity 
to undertake the physical tasks of daily living.65 There is 
robust evidence that higher scores on these measures are 
associated with lower rates of mortality, and there is more 
limited evidence of lower risks of morbidity, and of age-re-
lated patterns of change.65
Height and weight– Height and weight will be collected 
in order to calculate the body mass index (BMI) according 
to the formula BMI=weight (kg)/height (m)2.
Grip strength- JAMAR hydraulic hand dynamometer is 
the most widely used instrument with established test-re-
test, inter-rater and intrarater reliability.66
Chair rise- The 30 s Chair Stand Test will be used to 
assess lower body strength.67 This test provides a reliable 
and valid indicator of strength in adequately active, older 
adults form the general population. Intraclass correla-
tion coefficients for test-retest are 0.84 for men and 0.92 
for women, using one-way analysis of variance, and a 
non-significant change in scores between days indicating 
good reliability.67 As expected, chair-stand performance 
decreased significantly with increasing age (P<0.01) and 
was statistically significantly lower for participants who 
were less active (P<0.0001).67
Walking speed– In order to assess normal comfortable 
walking speed and maximum walking speed, a timed 
10-Metre Walk Test will be used. This test has been vali-
dated in 230 healthy volunteers.62 The mean comfortable 
gait speed ranged from 127.2 cm/s (women aged 70 to 
79 years) to 146.2 cm/s (men aged 40–49 years). Mean 
maximum gait speed ranged from 174.9 cm/s (women 
aged 70–79 years) to 253.3 cm/s (men aged 20–29 years). 
The correlation coefficients of both gait speed measures 
was higher than 0.903, and correlated significantly with 
age (r>−0.210) and height (r>0.220).62
A photograph of the hands will be taken at the end 
of this section to assess inflammation, finger nodes, and 
other rheumatological and osteoarthritis-related changes 
at the hand.
The Hip Disability and Osteoarthritis Outcome Score 
measures patient’s opinions about their hip and associ-
ated problems. It examines pain, symptoms, function in 
activities of daily living (ADL) and function in sport and 
recreation. It has been used in subjects with hip disability 
with or without hip osteoarthritis68 (Additional Optional 
Module).
The Knee Injury and Osteoarthritis Outcome 
Score examines pain frequency and severity during 
functional activities, and symptoms such as the severity 
of knee stiffness, the presence of swelling, grinding or 
clicking, difficulty in ADL, with sport and recreation, and 
knee-related quality of life. It is intended for use in young 
and middle-aged populations with post-traumatic osteoar-
thritis, in addition to those with injuries who may go on to 
develop secondary osteoarthritis69 (Additional Optional 
Module).
The Questionnaire to Identify Knee Symptoms is used 
for early osteoarthritis, and understanding symptomology 
and potential adaptation to activity before osteoarthritis 
has been clinically diagnosed. It has been developed in 
adults aged 40–65 years with evidence of ongoing knee 
problems and recommended for use in studies exploring 
early osteoarthritis70 (Additional Optional Module).
Cognitive ability assessment
The methodology used in the 1946 birth cohort will also 
be followed for the assessment of cognitive capability.59 
Tests and questionnaires will be described according 
their belonging to the Core Module or the Additional 
Optional Module, and by domain (figure 1).
The MMSE71 is a widely used 30-point screening tool for 
cognitive impairment within clinical practice, assessing 
multiple cognitive domains including orientation to time 
and place; registration; attention  ±calculation; recall; 
language; repetition; reading; writing; visuospatial func-
tion; and executive function and praxis.
The Logical Memory from the Wechsler Memory 
Scale-Revised72 test assesses free recall of a short story. 
The participant is asked to recall the story immediately 
and after 20 min delay.
FNAME-12A is a modified version of the 16-item 
Face-Name Associative Memory Exam (FNAME-16). 
FNAME-12A has fewer stimuli and additional learning 
trials which have been found to be well tolerated by 
those with mild cognitive impairment, while remaining 
challenging in cognitively normal older adults.73 
FNAME-12A has demonstrated psychometric equivalence 
with FNAME-16, which has been shown to be related to 
the beta-amyloid burden in cognitively normal elderly 
people.74 FNAME-12A requires the participant to learn 
12 face-name and face-occupation pairs. Participants 
are given two exposures to all 12 face-name/occupation 
pairs. After each exposure, and following 5 min delay, 
participants are asked for the name and occupation asso-
ciated with each face. After 30 min delay they are shown 
three faces and asked to identify the face that they recog-
nise and give the name and occupation. Given multiple 
options to choose from, they are then asked to select the 
name and/or occupation associated with the face.
The Task-set Shifting/Response Inhibition75 76 task 
examines the relationship between executive tasks of task-
switching/preparation time. In the arrow only condition, 
participants are shown the cue ‘arrow’. Following a short 
delay they must respond to the direction of the arrow 
(‘right’ or ‘left’). In the word only condition, participants 
are shown the cue ‘word’. Following a short delay they 
must respond to the direction of the word (‘right’ or 
‘left’). There is a switching condition in which the partici-
pant is shown the cue ‘arrow’ or ‘word’. Following a delay, 
both a combined arrow and word stimulus appears. The 
stimulus is either congruent (left arrow and left word), 
or incongruent (left arrow and right word). Trials in the 
switching task are categorised into switch and non-switch. 
In a non-switch trial the cue is the same as for the immedi-
ately preceding trial. In a switch trial the cue differs from 
the immediately preceding trial.
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The Digit-Symbol Substitution Test, from the Wechsler 
Adult Intelligence Scale-Revised77 explores attention and 
psychomotor speed. Participants are given a code table 
displaying digits (from 1 to 9); each digit is paired with a 
symbol. The participant is required to fill in blank squares 
with the corresponding symbol for each digit as shown 
in the code table. They are given 90 s to fill in as many 
squares as possible.
The Visual Short-term Memory Binding78 79 test 
requires the participant to view one or three fractal 
objects, presented simultaneously in random locations 
on the screen. The participant is asked to remember both 
the objects and their location. After a delay of 1 s or 4 s 
they have to make a forced choice between one of the 
displayed fractals (the target) and a ‘dummy’ fractal. 
Participants are required to touch the object they think 
has been previously presented and ‘drag’ it on the touch 
screen to its remembered, original location. The binding 
of such featured information has been shown to be 
vulnerable in asymptomatic FAD mutation carriers.79
NART was specially designed to provide a means of 
estimating the premorbid intelligence levels of adults 
suspected of suffering from intellectual deterioration.80 
NART comprises a list of 50 words printed in order of 
increasing difficulty. The words are relatively short in 
order to avoid the possible adverse effects of stimulus 
complexity on the reading of dementing subjects, and 
they are all 'irregular' with respect to the common rules 
of pronunciation in order to minimise the possibility 
of reading by phonemic decoding rather than word 
recognition.80
Visuomotor Integration81 is a circle tracing task which 
includes both direct and indirect visual feedback condi-
tions. Continuous performance measures are provided 
including accuracy, speed, and speed of error detection 
and correction. The test has revealed changes in speed 
and accuracy in Huntington disease mutation carriers 
more than 10 years before expected age-of-onset (Addi-
tional Optional Module).
The Matrix Reasoning from the Wechsler Abbreviated Scale 
of Intelligence82 test assesses non-verbal reasoning. The 
participant is shown a matrix of geometrical shapes with 
a section missing. They are required to select the option 
that completes the matrix (Additional Optional Module).
In the irrelevant distractor paradigm83 participants are 
given a computerised letter-search task and are required 
to make a rapid decision as to whether the target letter 
‘X’ or ‘N’ has appeared in the search display (in either 
low or high load conditions). On some of the trials, a 
task-irrelevant distractor (a cartoon character) appears 
on the outside of the search display. The task evaluates 
the extent to which attention is captured and captivated 
by the distractor (Additional Optional Module).
neurological clinical assessment
The neurological assessment of participants is needed 
for detecting any subtle neurological sign, and to estab-
lish a baseline for the absence of one or more signs. A 
video-recorded standard neurological examination will 
be included as part of the Core Module. An additional 
test of self-reported impairment, mainly due to move-
ment disorders, will be administered as part of the Addi-
tional Optional Module (figure 1).
A standard video recording of each participant 
accessing the study at one of the clinics will be performed 
and evaluated by a clinical neurologist. The assessment 
includes examination of strength, coordination, balance, 
ocular movements, cranial nerves, gait and repeated 
movements. The examination also includes a test of knee 
functionality.84
Information on potential movement disorders will be 
collected using the Unified Parkinson’s Disease Rating 
Scale, part II. This includes self-reported ratings on several 
motor domains, including speech, saliva and drooling, 
chewing and swallowing, eating, dressing, hygiene, hand-
writing, hobbies, turning in bed, tremor, standing up, 
walking and balance, and freezing (Additional Optional 
Module).
Intermediate neurological end points
In addition to neurological signs and symptoms, some 
intermediate outcomes have been recognised as part 
of the complex clinical picture of movement disorders, 
manifesting before the onset of the movement impair-
ment itself. These will be investigated with three tests 
described below (figure 1).
The BRAIN tap test is a simple computerised test which 
uses a standard keyboard, based on alternating finger 
tapping. It has been developed to quantify and define 
upper limb motor function.85 The test generates four 
variables: (1) the Kinesia Score which is defined as the 
number of keystrokes in 60 s; (2) the akinesia time which 
is defined as the cumulative time that keys are depressed; 
(3) the Dysmetria Score which is calculated as a weighted 
index using the number of incorrectly hit keys corrected 
for speed; and (4) the In-coordination Score, which is a 
measure of rhythmicity corresponding to the variance 
of the time interval between keystrokes.85 The BRAIN 
test assesses speed, accuracy and rhythmicity of upper 
limb movements, regardless of their causes. The results 
of the test correlate well with PD clinical rating scales 
and with cerebellar dysfunction.85 The BRAIN tap test 
is available online at https://www. braintaptest. com/ en_ 
GB and VG has obtained access for generating tokens for 
administering the test to participants (A Noyce, personal 
communication).
The University of Pennsylvania Smell Test is a measure-
ment of the individual’s ability to detect odours.86 The 
test, which takes only a few minutes, consists of four 
different 10-page booklets (total of 40 questions). On 
each page, the participant is invited to sniff a different 
‘scratch and sniff’ strip, embedded with an odorant. For 
each odour, the participant can choose among four multi-
ple-choice answers. The total score of each participant is 
compared with scores in a normative database from 4000 
normal individuals87 (Additional Optional Module).
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The RBD Screening Questionnaire (RBDSQ) is a vali-
dated 10-item patient self-rating questionnaire (maximum 
total score 13 points) covering the clinical features of 
RBDs.88 The RBDSQ was validated on 54 patients with poly-
somnographically confirmed RBD, 160 control subjects 
in whom RBD was excluded by history and polysomnog-
raphy and 133 unselected healthy subjects. Applying a 
positivity threshold of 5 points, RBDSQ had a sensitivity 
of 0.96 and a specificity of 0.56 comparing patients with 
RBD with patients with other sleep disturbances. A speci-
ficity of 0.92 was calculated when comparing patients with 
RBD with patients without sleep disturbances88 (Addi-
tional Optional Module).
blood and saliva sample collection, and biobanking
Participants seen in the research clinics will be asked 
to donate a blood sample for testing for tau protein, 
NF levels, full blood count analysis and to obtain data 
for GWAS. Samples of serum, plasma and DNA will be 
collected and processed according to a prespecified 
protocol and stored in a freezer at −80°C at the Blizard 
Institute (Queen Mary, University of London). All partic-
ipants will also asked to donate a blood sample through 
a dried blood spot test and a saliva sample (in order to 
obtain DNA where phlebotomy is not possible).
Samples will be tested to measure the expression of 
NF-L , an NF subunit showing consistent and reproduc-
ible measurements in plasma/serum using a newly devel-
oped sensitive methodology exploiting single molecule 
trapping and measurement by ELISA Single Molecule 
Array (SIMOA).89–91 The use of both NF-L and NF-H 
allows for the determination of different markers whose 
dynamics of release into biofluids following injury vary 
according to their particular chemical structure. NF-L has 
shown good levels of linearity on dilution experiments, 
suggesting that confounders like aggregation or immune 
response may not interfere with its measurements. The 
different NF-H phosphorylation states in blood may in 
turn provide more information on the systemic biolog-
ical changes induced by trauma. The relative low abun-
dance of these proteins in blood, in the absence of CSF, 
which is normally more enriched with the by-products 
of neuronal destruction, will not represent a major 
obstacle, as analytical sensitivity has evolved with the 
development of novel assays which cover the lower end 
of these dynamic protein ranges. SIMOA, the proposed 
methodology for the target biomarkers, is now emerging 
as the core technique for the measurement of structural 
proteins, down to the femptomolar end of the spectrum. 
A novel SIMOA-based assay for the measurement of tau 
in blood is now available. This development offers a wide 
range of opportunities based on the possibility of over-
coming the limitations imposed by CSF collection by 
lumbar puncture.
GWAS will be conducted at University College London 
(UCL) in the lab led by Prof John Hardy.
Multimedia database set-up and management
A multimedia database will be established as part of this 
project. The final data set will include questionnaire and 
tests data (see figure 1), in addition to the video-recorded 
neurological examination. These data will be also linked 
to the stored blood samples through a unique identifier.
The data will be stored in mirror, anonymised data sets 
at the London School of Hygiene and Tropical Medicine 
and Queen Mary, University of London (QMUL) on 
secure servers, and access will be regulated by the study 
Principal Investigators (PIs) who are ultimately respon-
sible for maintaining confidentiality and data protection. 
Only the researcher(s) employed on this study will have 
access to subject identifiable information. Identifiable 
information (name, date of birth and address) will be 
removed prior to analysis and subjects will be identified 
by pseudoanonymised codes. Personal data and key codes 
for pseudoanonymisation will be stored in a database with 
restricted access. Before conducting the statistical anal-
yses, checks will undertaken to ensure data quality.
statistical analysis
Descriptive statistical methods (geometrical means, 
geometrical SDs and 95% CIs) will be used to summarise 
the rugby history and lifestyle exposure data. Analyses 
linking a history of head trauma with neurological symp-
toms (obtained by questionnaire and neurobehavioural 
tests) will then be performed. Parameters of physical 
and cognitive capability, alongside clinical neurological 
intermediate end points, will initially be dichotomised 
(yes/no symptoms), and analysed with prevalence ORs 
using logistic regression.92 We will also analyse contin-
uous outcome measures using multiple linear regres-
sion. In addition to analysing individual symptoms, we 
will assess associations with domains of symptoms (ie, 
physical and cognitive capability). For this purpose 
we will use cut points previously published in the liter-
ature,93 particularly related to the 1946 birth cohort 
whose testing protocol was used. For analyses involving 
repeated measurements (neurobehavioural testing) 
assessing acute and chronic effects, we will use multilevel 
models. Analyses will be adjusted for age, sex and alcohol 
consumption.
Finally, we will compare neurological outcomes assessed 
by questionnaire with those assessed by computer-admin-
istered tests using kappa-statistics (and in case of contin-
uous outcomes linear regression analyses). We will also 
compare the strengths of the associations with exposure 
between both outcome measures.
study size and power
We aim to invite 205 participants to participate, approx-
imately half of whom have been exposed to concussion 
during their career (M Cross, personal communication). 
We conservatively estimate that about 150 former players 
will participate. Based on previous studies, the SDs of 
the psychometric tests are in the range of 8%–15% of 
the absolute value; assuming a conservative figure of 
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15% overall, the study will have more than 95% power to 
detect a 10% difference, and 80% power to detect a 7% 
difference in psychometric test scores between exposed 
(to concussion) and non-exposed participants.
Limitations
The main limitation of this study is the cross-sectional 
design. Data on lifetime exposure (history of concus-
sion) and health outcomes are collected at one time 
point, making data subject to recall bias. Participants with 
a poorer health, or sentiment of discontent with their 
health status, may overestimate concussive exposure, if 
they attribute their poor health to it.
However, this cross-sectional study design will provide 
meaningful data on the burden of ill health and neuro-
logical health among retired rugby players, in a relatively 
short 2-year time frame. Depending on results (and avail-
ability of additional funding), this study could inform a 
more detailed, and time-intensive cohort study, aimed 
at assessing the association between concussion in rugby 
players and health outcomes prospectively.
A direct consequence of the cross-sectional design 
is an intrinsic risk of selection bias. Rugby players who 
have developed serious neurodegenerative conditions 
(or have died from them) in the meantime are less likely 
(or not able) to participate in the study thus limiting our 
sample to a subsample of healthier retired rugby players. 
On the other hand, it is possible that former players who 
experience some cognitive symptoms will be more keen 
to participate in the study, to seek reassurance and be 
examined in more detail.
Irrespective of these considerations, our investi-
gation of the association between the exposure to 
sporting concussion and later-life general and neuro-
logical health outcomes remains valid, despite a smaller 
range of health outcomes diminishing the power for 
detecting an association as significant. Nonetheless, 
the power calculation for this study is calculated on the 
basis of continuous outcome measures (ie, neurocog-
nitive tests or grip strength measurement) making this 
study adequately powered to detect the potential asso-
ciations, based on the expected number of recruited 
participants.
It is worth noting that results from this study might be not 
immediately applicable to current rugby players, due to this 
cohort’s former playing status, history of amateur playing 
exposure and alterations to rules and conditions, aimed at 
increasing player safety over recent years, which will have 
altered the player’s overall exposure to concussive events.
Ethics and dissemination
The study in general is focusing on subclinical problems 
(eg, slightly lower than average scores in cognitive func-
tion tests) which would not usually require any medical 
attention. If any problems are identified, we will (with the 
permission of the study participant) refer participants to 
their primary care physician. The consent form includes 
the following statement:
I wish to inform my GP that I am taking part to this 
study
I wish the study team to inform my GP of any unusual 
test result
This study will provide unique insight into the phys-
ical and neurological health of retired rugby players who 
are now aged 50 years or more. This is valuable infor-
mation per se, potentially comparable with other occu-
pational cohorts or the general population (accepting 
the potential for bias discussed previously in comparing 
these samples). Moreover, within this study, data will be 
analysed as a function of the history of TBI and concus-
sion during their careers, and therefore assess associa-
tions between the history of reported concussive injuries 
and health-related outcomes.
Importantly, the neurological examination and collec-
tion of intermediate neurological outcomes allows the 
detection of subtle preclinical changes that might be asso-
ciated with future risk of developing a neurodegenerative 
condition. Studying to what extent these changes are also 
associated with history of concussion will allow an estima-
tion of the impact of concussion on the onset of neuro-
degenerative diseases in rugby players, thus providing the 
basis for future prospective studies.
A novel aspect of this project is the molecular compo-
nent: clinical and neurocognitive findings will be particu-
larly reinforced by the measurement of blood biomarkers. 
These will give a quantitative measurement of active 
neurodegeneration (NF-L) and of possible CTE (tau), to 
be analysed conjunctly with the health-related outcomes 
and personal history of concussion.
Also, relying on a number characteristics of the rugby 
playing history collected (ie, length of playing at elite level, 
position played, numbers of games played, age when started 
playing), it will be possible to identify potential categories 
of players at potentially increased risks of health-related 
outcomes.
This study may identify a small deviation from normality 
in any of the continuous measures collected via cogni-
tive and other tests (ie, grip strength, memory function, 
walking speed, etc). This will be mainly investigated in 
association with a history of frequent concussions, or 
other head traumas. The investigators will interpret the 
results based on the continuum of distribution of the test 
outcomes, which will not have specific clinical transla-
tion. However, it should be emphasised that although this 
study is unlikely to identify patterns suggesting a clinical 
disease in any of the participants, if these are identified, 
then the relevant participant(s) will be referred to appro-
priate medical services.
These data will be disseminated initially to players 
and sports governing bodies, and through peer-re-
viewed publication and conference presentation, in 
order to begin to establish an evidence basis for the 
association between exposure to sports-related concus-
sion, and potential later-life cognitive and neurological 
impairment.
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